Articles From: Abbott Included In Top 10 Best Companies by Working Mother Magazine to Abcam Establishes New Direct Service for Australia and New Zealand


Moms Value Paid Parental Leave and Flexible Work Arrangements as Abbott Is Recognized for the Fourteenth Consecutive Year ABBOTT PARK, Ill., Sept.
Sign-up for Abbott Included In Top 10 Best Companies by Working Mother Magazine investment picks
- Abbott's Absorb Bioresorbable Vascular Scaffold (BVS) is a revolutionary medical device used in the heart that functions like a stent but dissolves over time - ABSORB IV will compare Absorb to a best-in-class, metallic drug eluting stent in people with coronary artery disease, the most common type of heart disease - Trial will prospectively measure rates of angina, or chest pain, in the first randomized controlled heart stent trial with angina as a primary endpoint to assess impact of angina on healthcare costs and quality of life ABBOTT PARK, Ill., Sept.
Sign-up for Abbott Initiates ABSORB IV Trial to Evaluate Quality of Life and Cost Savings of Dissolving Heart Device investment picks
New Study Shows Most Breastfeeding Moms Do Not Consistently Consume Enough Ideal Levels of These Key Nutrients ABBOTT PARK, Ill., July 24, 2014 /PRNewswire/ -- Nutrition needs are greater when breastfeeding than any other time in a woman's life, including pregnancy, yet new research reveals diet alone may not be enough to meet the high nutritional needs during this important time for mom and baby.[1]  Abbott (NYSE: ABT) , the makers of Similac ® and experts in infant nutrition for nearly 90 years, studied the diets of more than 80 lactating women to assess how their nutritional intake compared to dietary recommendations.
Sign-up for Abbott Introduces New Similac® Breastfeeding Supplement with DHA, Lutein and Vitamin E investment picks
2014/9/26
TIDMABT RNS Number : 7926S Abbott Laboratories 26 September 2014 Abbott Completes Acquisition of CFR Pharmaceuticals; Announces Results of Tender Offer for CFR Shares Acquisition enhances Abbott's position in Latin America, more than doubling its branded generics pharmaceutical sales and presence in the fast-growing region ABBOTT PARK, Ill., Sept.
Sign-up for Abbott Laboratories ABT Announces Acquisition of CFR Pharmaceuticals investment picks
NEW YORK (MarketWatch) -- Abbott Laboratories shares (ABT) climbed more than 2% in premarket trade Wednesday, after the company reported better-than-expected second-quarter profit and sales and raised its outlook for the full year.
Sign-up for Abbott Labs shares climb 2.7% as profit, sales top estimates investment picks
By Anna Prior Abbott Laboratories said it will sell its developed markets branded generics pharmaceuticals business to Mylan Inc. in a $5.3 billion deal that includes the formation of a new publicly traded company.
Sign-up for Abbott Labs to sell part of generics business for $5.3 billion investment picks
- Abbott Achieved Top Industry Scores for Economic and Social Performance - Company Recognized for Sustainability Leadership for 10 Consecutive Years ABBOTT PARK, Ill., Sept.
Sign-up for Abbott Once Again Named the Industry Leader for Responsible and Sustainable Business on the Dow Jones Sustainability Index (DJSI) investment picks
- FreeStyle Libre System eliminates routine finger pricks for glucose measurements1 and requires no finger pricks for calibration - Available for people living with diabetes in several European markets beginning in the coming weeks - Advanced Ambulatory Glucose Profile software presents data in a user-friendly, visual chart, enabling productive treatment discussions ABBOTT PARK, Ill., Sept.
Sign-up for Abbott Receives CE Mark for FreeStyle® Libre, a Revolutionary Glucose Monitoring System for People with Diabetes investment picks
2014/7/16
- Second-Quarter Ongoing EPS of $0.54, Above Previous Guidance Range and Representing Double-Digit Earnings-Per-Share Growth - - GAAP EPS from Continuing Operations of $0.30 - - Raises Full-Year 2014 EPS Guidance Range - - Continues to Shape Abbott for Long-Term Growth with Agreements to Acquire CFR Pharmaceuticals and Veropharm, and to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan - ABBOTT PARK, Ill., July 16, 2014 /PRNewswire/ -- Abbott today announced financial results for the second quarter ended June 30, 2014 .
Sign-up for Abbott Reports Second-Quarter 2014 Results investment picks
Abbott will retain its branded generics pharmaceuticals business in emerging markets Transaction expected to positively impact Abbott's sales and ongoing earnings-per-share growth rates ABBOTT PARK, Ill., July 14, 2014 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that it will sell its developed markets branded generics pharmaceuticals business to Mylan for equity ownership of a newly formed entity that will combine Mylan's existing business and Abbott's developed markets pharmaceuticals business, and will be a publicly traded company.
Sign-up for Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan investment picks
2014/7/28
ABBOTT PARK, Ill., July 28, 2014 /PRNewswire/ -- Clinical laboratories around the world are helping to improve patient care while navigating an evolving health care environment.
Sign-up for Abbott to Showcase Innovations to Help Labs Solve Health Care Challenges at the American Association for Clinical Chemistry Lab Expo investment picks
- Calico to create a leading R&D facility in the San Francisco Bay Area focused on aging and age-related diseases, including neurodegeneration and cancer - AbbVie and Calico may co-invest up to $1.5 billion, utilizing Calico's discovery and early development capabilities and AbbVie's broad research, development and commercial expertise to advance innovative new therapies NORTH CHICAGO, Ill.
Sign-up for AbbVie And Calico Announce A Novel Collaboration To Accelerate The Discovery, Development And Commercialization Of New Therapies investment picks
- AbbVie will donate $10 to Cystic Fibrosis Research, Inc. (CFRI) for every recipe collected between August 1 and September 15, 2014, up to $10,000 - AbbVie will donate an additional $5,000 to CFRI if 50 recipes are submitted before Friday, August 8 - CFRI will provide educational resources and support for increasing awareness among patients on the importance of maintaining a proper CF diet NORTH CHICAGO , Ill.
Sign-up for AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program investment picks
- Currently no approved treatment options available for patients living with HS, a skin disease which impacts approximately 1 percent of the adult population worldwide1,2 - PIONEER I first Phase 3 trial to evaluate the investigational use of HUMIRA in patients with moderate-to-severe HS3 - Results show HUMIRA meets primary endpoint3 COPENHAGEN, Denmark , Sept.
Sign-up for AbbVie Announces Pivotal Phase 3 Data Evaluating Efficacy of HUMIRA® (adalimumab) in Patients with Hidradenitis Suppurativa (HS), a Chronic Inflammatory Skin Disease investment picks
LONDON (MarketWatch) -- U.S. drug maker AbbVie Inc. (ABBV) said on Friday it will buy Irish pharmaceutical firm Shire PLC (uk:shp) in a deal valued at $54 billion, a move that could release it from U.S. corporate taxes.
Sign-up for AbbVie confirms $54 billion merger with Shire investment picks
2014/8/18
- Recipients will compete for public votes for a chance to win one of two Thriving Undergraduate and Graduate Scholar awards - Supporters can vote for recipients at www.AbbVieCFScholarship.com NORTH CHICAGO, Ill.
Sign-up for AbbVie Cystic Fibrosis Scholarship Program Awards 40 Student Scholars With Annual Academic Awards investment picks
NORTH CHICAGO, Ill.
Sign-up for AbbVie Declares Quarterly Dividend investment picks
2014/7/9
By Hester Plumridge AbbVie Inc.(ABBV) was forced Wednesday to retract statements it made the previous day on shareholder support for its $51.62 billion takeover offer for London-listed Shire PLC .
Sign-up for AbbVie forced to retract statements in $51 billion Shire bid investment picks
- AbbVie presents preliminary data from randomized phase 2 trial of veliparib in non-small cell lung cancer - Additional results to be presented on a Phase 1 trial in Japanese patients with NSCLC NORTH CHICAGO, Ill.
Sign-up for AbbVie Presents Results from Multiple Studies of Investigational Compound Veliparib in Patients with Non-Small Cell Lung Cancer at the European Society for Medical Oncology Annual Congress investment picks
2014/7/8
By Ian Walker LONDON--
Sign-up for AbbVie raises offer for Shire investment picks
- Results from Phase I program in glioblastoma multiforme presented at ASCO earlier this year NORTH CHICAGO, Ill.
Sign-up for AbbVie Receives EMA and FDA Orphan Drug Designation for Investigational Compound ABT-414 in the Treatment of Glioblastoma Multiforme investment picks
- Reports Second-Quarter Adjusted EPS of $0.82, Above Previous Guidance Range of $0.75 to $0.77 (Reports GAAP EPS of $0.68) - Delivers Second-Quarter Revenue of $4.926 Billion, an Increase of 5.0 Percent Over Second-Quarter 2013 (Up 4.8 Percent On an Operational Basis); Revenue Up 12.3 Percent Operationally Excluding Lipid Sales Due to Loss of Exclusivity - Revenue Growth Reflects 26.2 Percent Global Reported Sales Growth from HUMIRA (Up 25.4 Percent On an Operational Basis) and Strong Growth from Other Key Products - Pipeline Continues to Advance Including Phase 3 Start for ABT-888, Positive Phase 3 Data for Daclizumab, Priority Review (FDA) and Accelerated Assessment (EMA) of our HCV Program, Positive Data from Next-Generation HCV Program and ABT-414 for Glioblastoma - Continues to Enhance the Company's Position and Shape AbbVie for the Long-Term with Agreement to Merge with Shire, Creating a Larger and More Diversified Biopharmaceutical Company and Driving
Sign-up for AbbVie Reports Second-Quarter 2014 Financial Results investment picks
2014/7/23
NORTH CHICAGO, Ill.
Sign-up for AbbVie to Host Second-Quarter Earnings Conference Call investment picks
NORTH CHICAGO, Ill.
Sign-up for AbbVie to Present at Morgan Stanley Global Healthcare Conference investment picks
Presentations include first Phase 2 results evaluating investigational compound Veliparib in patients with non-small cell lung cancer NORTH CHICAGO, Ill.
Sign-up for AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting investment picks
By Hester Plumridge LONDON --
Sign-up for AbbVie woes Shire into $54 billion acquisition deal investment picks
-- HUMIRA is now indicated to treat pediatric patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate --
Sign-up for AbbVie's HUMIRA® (adalimumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderately to Severely Active Crohn's Disease investment picks
Abcam plc, a global leader in the manufacture and supply of innovative protein research tools and services, and Cell Marque Corporation, a provider of antibodies and reagents for diagnostic immunohistochemistry, announced today they have signed a global 10-year strategic marketing agreement for Abcam’s in vitro diagnostic (IVD) immunohistochemistry (IHC) RabMAb ® primary antibody portfolio.
Sign-up for Abcam and Cell Marque Sign Global Strategic Marketing Agreement For IVD IHC RabMAb Antibodies investment picks
2014/8/12
Abcam plc, a global leader in the supply of innovative protein research tools, announced today it has established a direct service to Australia and New Zealand.
Sign-up for Abcam Establishes New Direct Service for Australia and New Zealand investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Abbott Included In Top 10 Best Companies by Working Mother Magazine to Abcam Establishes New Direct Service for Australia and New Zealand
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices